By what date will a peer-reviewed/credible study report a laboratory Mus musculus (mouse), under any experimental genetic, pharmacological, or dietary anti-aging intervention, with a documented maximum lifespan (e.g. longest-lived individual, or 90th-percentile survival) exceeding the current longstanding record of approximately 58 months (~4.9 years), held by growth-hormone-receptor-knockout (GHRKO) mice (the 'Methuselah Mouse Prize' longevity record, established in the mid-2000s)?

rationale:

Status Quo and Biological Baseline

As of August 2026, the maximum lifespan record for a laboratory mouse remains the ~58 months (1,819 days) achieved by a growth-hormone-receptor-knockout (GHRKO) mouse in the mid-2000s 3 sources. Despite decades of subsequent research, mainstream geroscience programs like the NIA Interventions Testing Program (ITP) have successfully extended median and 90th-percentile lifespans through interventions like rapamycin, acarbose, and 17α-estradiol, but have consistently fallen far short of the 1,819-day ceiling 3 sources. The closest verified near-misses remain well behind; for instance, the single longest-lived mouse in a massive Jackson Lab Diversity Outbred dietary-restriction cohort reached 53.9 months (~1,640 days) pmc.ncbi.nlm.nih.gov.

The Near-Term Pre-Print Wildcard

Near-term probabilities (2030–2035) are shaped almost entirely by a heavily contested preprint from Lanna/SenTcell ("CD4⁺ T cells confer transplantable rejuvenation via Rivers of telomeres") claiming that adoptive cell transfer allowed mice to live to "nearly five years" 3 sources. This claim carries massive red flags: it is company-funded, features a tiny treated cohort (n≈10), relies on abnormally short-lived controls, and contains widely flagged internal inconsistencies 55 sources. Furthermore, even if published in a peer-reviewed journal, a finding of "nearly five years" might not technically exceed the 1,819-day benchmark. Nonetheless, the possibility that this or a similar outlier from an ongoing large cohort sneaks into a credible publication provides a persistent near-term hazard rate.

Structural Constraints and Outlier Probability

Breaking this record will likely require a lucky extreme outlier in a massively scaled combination study, rather than a reliable cohort-wide maximum lifespan shift. Fortunately, capital and effort in geroscience are rising, with large, well-powered programs like the LEV Foundation's Robust Mouse Rejuvenation (RMR2) and the Astera/Buck Rejuvenome testing cyclic dosing and combination interventions levf.org. Because resolution requires only a single reported individual (which could appear incidentally in a supplementary table), the statistical chance of an outlier crossing the 58-month threshold rises as the absolute number of treated, long-lived mice grows.

Timeline and Long-Term Horizon

The base rate is exceptionally slow due to the logistics of longevity research: husbandry alone for a record-breaking mouse requires over five years, plus time for peer review and publication. Studies initiating combination therapies today will not generate reports until 2032 or later. Therefore, the median sits in the mid-2040s, allowing time for current and next-generation large-scale combination trials (e.g., GHRKO backgrounds paired with rapamycin, trametinib, or partial reprogramming) to fully mature. A substantial right tail extends well into the 2070s, reflecting the very real possibility that mouse maximum lifespan faces a hard biological wall (e.g., universal late-life cancer incidence) that even aggressive combination therapies merely compress rather than breach.